Skip to main content

Advertisement

Table 5 Analyses of Lymphocyte Subsets in Metastatic ALNs(a) in Women with LLABCs(b) Undergoing NAC(c): Comparison of Metastatic ALNs with a PCR with those without a PCR

From: Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC

Lymphocyte Subsets (n = 24) Groups ALN Median (Range) P Value(f)
CD4+ Pathological Complete Response (PCR, n = 10) 61.0 (32.0-75.0)(d) 0.172
Non Pathological Complete Response (Non PCR, n = 14) 69.0 (36.0-74.0)
CD8+ Pathological Complete Response (PCR, n = 10) 27.0 (13.4-40.0)(d) 0.048g
Non Pathological Complete Response (Non PCR, n = 14) 19.5 (10.4-30.0)
FOXP3+ Pathological Complete Response (PCR, n = 10) 3.1 (0.2-6.9)(d) 0.019g
Non Pathological Complete Response (Non PCR, n = 14) 6.5 (1.7-10.8)
CTLA-4+ Pathological Complete Response (PCR, n = 10) 5.7 (0.6-29.6)(e) 0.341
Non Pathological Complete Response (Non PCR, n = 14) 11.2 (3.2-38.6)
CD56+ Pathological Complete Response (PCR, n = 10) 19.7 (2.2-60.4)(e) 0.472
Non Pathological Complete Response (Non PCR, n = 14) 15.9 (6.8-39.0)
  1. (a)ALNs: Axillary lymph nodes (paracortical areas: tumour deposits excluded); (b)LLABCs: Large and locally advanced breast cancers; (c)NAC: Neoadjuvant chemotherapy; (d)Average percentage of positively stained cells out of all the lymphoid cells in the ALN sections (CD4+ and CD8+ and FOXP3+ T cells); (e)Average cell count of positively stained cells per 400× high-power field in the ALN sections (CTLA-4+ T cells and CD56+ NK cells); (f)Mann-Whitney U test; g Statistically significant